BSX and ANPI This was last old piece of info i had. Any update
besides liberte not cutting?
tia
NATICK, Mass. (AP) -- Medical device maker Boston Scientific Corp. said Tuesday it received additional European approval for its Taxus Liberte drug-coated stent.
The company said it received a CE mark for the Liberte to treat in-stent restenosis, or when tissue grows through the mesh of a stent to close up the blood vessel. It also received approval to treat total occlusions, or when the vessel becomes completely blocked. The new uses apply to patients with coronary artery disease including those who suffer from heart attacks.
Stents are tiny wire mesh tubes that are expanded inside diseased blood vessels to keep them open. Drug-coated stents help prevent tissue from growing back through the mesh.
Boston Scientific said it is the first company in Europe to receive these additional indications for a drug-coated stent.
The Liberte received its original CE Mark to treat coronary artery disease in September.
Separately, Boston Scientific and specialty drug maker Angiotech Pharmaceuticals Inc. said that in a Liberte clinical trial, the stent had a target vessel revascularization rate of 8 percent, and a target lesion revascularization rate of 5.7 percent.
Target lesion revascularization means a closing up of the blood vessel around the area where the stent was placed, and target vessel revascularization is a closure in the same vessel but somewhere else.
The study also compared the Liberte with the company's older Taxus Express2 stent, and showed the Liberte could be placed more quickly, in an average 47.8 minutes compared with 53 minutes for the Express2.
The complication rate for the Liberte was also lower at 3.1 percent of procedures, compared with 6 percent for the Express2.
Angiotech provides the cancer drug paclitaxel exclusively to cover Boston Scientific's stents.
Market Data 
Markets 
AI
